eFFECTOR Therapeutics nabs $40 mln Series B

By Iris Dorbian — 2 months ago

San Diego-based eFFECTOR Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $40 million in Series B funding. The investors were Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. In addition to the funding, eFFECTOR has named Dave Maki, managing partner of Altitude Life Science Ventures, to its board of directors.


Atreca grabs $56 mln Series A

By Iris Dorbian — 3 months ago

Redwood City, California-based biotech company Atreca Inc has closed $56 million in Series A funding. The investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline. Brookline Group LLC was the placement agent. PRESS RELEASE REDWOOD CITY, Calif.–(BUSINESS WIRE)–Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding […]


Alector snags $32 mln Series C

By Iris Dorbian — 5 months ago

Alector, a biotech company that focuses on treating Alzheimer’s disease and other neurodegenerative disorders, has secured $32 million in Series C financing. The investors included OrbiMed, Polaris Partners, Google Ventures, Topspin Partners and Mission Bay Capital.


Next Frontier Capital, Sears Capital, Z Investments and others back SiteOne

By Iris Dorbian — 7 months ago

Bozeman, Montana-based SiteOne Therapeutics, a developer of new drugs, has secured an undisclosed amount of funding. The investors included Next Frontier Capital, 2M Companies Inc, Sears Capital Management, Biobrit LLC, Mission Bay Capital and Z Investments. In addition to the funding, Will Price, founder and managing partner of Next Frontier Capital, has been added to SiteOne’s board of directors.


Mission Bay Fund II raises $25 mln

By Luisa Beltran — 9 months ago

Mission Bay Capital LLC said Monday it closed its second fund at $25 million. Fund II investors include several institutions and private individuals, including Jack Wadsworth, honorary chairman at Morgan Stanley Asia; Brook Byers, partner at venture capital firm Kleiner Perkins Caufield & Byers; the UCSF Foundation; the William K. Bowes, Jr. Foundation; Sobrato Capital; Capital Pacific; Novozymes; Chote Sophonpanich; Michael F. Koehn; and Leslie and Mac McQuown. Mission Bay Capital invests in life science companies emerging from the University of California and the San Francisco Bay Area.


Symic Biomedical snags $15 mln Series A

By Iris Dorbian — 1 year ago

San Francisco-based Symic Biomedical, a healthcare-focused biotech firm, has raised $15 million in Series A funding. Lilly Ventures led the round with participation from other investors that included Den Danske Forskningsfond, Mitsui Global Investment, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital and QB3 Partners. In addition to the funding, Symic Biomedical has appointed Dr. Armen Shanafelt, a general partner at Lilly Ventures and Dr. Claus Christiansen, chairman of Nordic Biosciences, to its board of directors.


Life Science Angels leads a $1.5 mln seed round in Zephyrus Biosciences

By Chris Witkowsky — 1 year ago

Life Science Angels has led a $1.5 million seed funding in biotech company Zephyrus Biosciences. Other investors in the seed round include Mission Bay Capital, The Angel Forum and the Stanford StartX Fund, as well as individual investors in the life science community. Zephyrus also raised $350,000 in a grant from the National Institute of Health and $10,000 from the U.C. Bakar Fellows Program.


Principia Biopharma nabs $50 mln Series B funds

By Iris Dorbian — 2 years ago

Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma’s board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.


eFFECTOR Therapeutics Raises $45 Million Series A

By Angela Sormani — 3 years ago

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.


Principia Biopharma Inks $12.5M

By Staff Report — 3 years ago

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.


Mission Bay Capital Fund Launches

By PEHub Administrator — 6 years ago

The California Institute of Quantitative Biosciences has formed a $7.5 million VC funding to provide startup capital for UC bioscience entrepreneurs and a long-term endowment for Qb3. It is being called the Mission Bay Capital Fund.